Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Anti-Nogo Receptor/NgR Antibody

Copy Product Info
🥰Excellent

Synonyms:

Catalog No. T9901A-1366 Copy Product Info
🥰Excellent
Anti-Nogo Receptor/NgR Antibody is a humanized monoclonal antibody targeting Nogo Receptor 1 (NgR1/RTN4R). NgR1 is a common receptor for CNS myelin-derived inhibitory factors (e.g., Nogo-A, MAG, and OMgp), the activation of which induces growth cone collapse and inhibits axonal regeneration. By specifically binding to NgR1, this antibody blocks the interaction between inhibitory ligands and the receptor, thereby lifting the restriction on neuronal growth and promoting axonal regeneration, compensatory sprouting, and synaptic plasticity. It is a vital tool for researching neural repair in spinal cord injury, stroke, and multiple sclerosis.

Anti-Nogo Receptor/NgR Antibody

Pack SizePriceUSA StockGlobal StockQuantity
1 mg$377InquiryInquiry
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Product Introduction

Bioactivity
Description
Anti-Nogo Receptor/NgR Antibody is a humanized monoclonal antibody targeting Nogo Receptor 1 (NgR1/RTN4R). NgR1 is a common receptor for CNS myelin-derived inhibitory factors (e.g., Nogo-A, MAG, and OMgp), the activation of which induces growth cone collapse and inhibits axonal regeneration. By specifically binding to NgR1, this antibody blocks the interaction between inhibitory ligands and the receptor, thereby lifting the restriction on neuronal growth and promoting axonal regeneration, compensatory sprouting, and synaptic plasticity. It is a vital tool for researching neural repair in spinal cord injury, stroke, and multiple sclerosis.
In vitro
In cell-based neurite outgrowth assays, Anti-Nogo Receptor/NgR Antibody effectively blocks the binding of myelin-associated inhibitors (Nogo, MAG, and OMgp) to NgR1-expressing neurons, significantly reversing growth cone collapse and promoting neurite extension in primary DRG or cortical neurons [1][2].
In vivo
In pharmacological studies using rat models of spinal cord hemisection or ischemic stroke, intrathecal or systemic administration of Anti-Nogo Receptor/NgR Antibody (such as mAb 50) led to marked enhancement of functional locomotor recovery, accompanied by increased axonal sprouting and structural plasticity within the lesioned central nervous system [1][2].
Reactivity
Human
Application
FACS
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Uniprot ID
TargetNogoReceptor/NgR
Antibody Information
IsotypeIgG2SA
Storage & Solubility Information
StorageStore at low temperature Store at -20°C Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: Anti-Nogo Receptor/NgR Antibody in vivo | Anti-Nogo Receptor/NgR Antibody in vitro